Claritev Appoints Technology Executive Jason Kap to Board of Directors, Bolstering Strategy to Transform Healthcare with Innovation and Insight Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a leading technology, data, and insights company focused on advancing affordability, transparency, and…
Andlauer Healthcare Group Reports Q1 2025 Financial Results and Announces UPS Acquisition Andlauer Healthcare Group Inc. (TSX: AND) (“AHG” or the “Company”) has released its financial results for the first quarter ended March 31, 2025, and announced a definitive agreement…
Healthcare Realty Reports First Quarter 2025 Financial Results and Declares Quarterly Dividend of $0.31 Per Share Healthcare Realty Trust Incorporated (NYSE: HR), a leading real estate investment trust (REIT) focused on owning, operating, and developing high-quality outpatient medical facilities across…
Baxter International Reports First-Quarter 2025 Results, Driven by Strategic Focus and Solid Operational Execution Baxter International Inc. (NYSE: BAX), a global leader in medical technology, today announced its financial results for the first quarter of 2025. The results reflect continued…
Cencora Impact Foundation Conference Champions Global Collaboration to Dismantle Barriers to Healthcare Access The Cencora Impact Foundation, a philanthropic arm of Cencora and an independent not-for-profit charitable organization, recently hosted its sixth annual Nonprofit Partner Conference, reinforcing its deep commitment…
Oklahoma Complete Health Unveils New and Expanded SoonerSelect Benefits to Improve Member Health and Well-Being in 2025 Oklahoma Complete Health is introducing a comprehensive set of new and upgraded benefits for its SoonerSelect members in 2025, continuing its mission to…
Genmab to Submit sBLA to FDA for Epcoritamab in Combination with Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma Genmab A/S (Nasdaq: GMAB) has announced its plan to submit a supplemental Biologics License Application (sBLA) to the U.S. Food…
InnoCare’s Next-Generation TRK Inhibitor Zurletrectinib Granted Priority Review by China’s NMPA for NTRK Fusion-Positive Tumors A prominent biopharmaceutical company dedicated to the development of innovative therapies for cancer and autoimmune diseases, announced a major regulatory milestone today. The Center for…
2025 Clinical Trials Outlook: Key Trends in Planned Initiations and Projected Completions A Preview of Trials Planned to Initiate and Estimated to Complete, offering a detailed look into the anticipated global clinical trial landscape for the coming year. Drawing on…
CareDx Posts Strong Q1 2025 Results, Driven by Revenue Growth and Strategic Advancements CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on transplant patient care, has reported financial results for the first quarter ended March 31, 2025. The…
Glaukos Corporation Reports Strong First Quarter 2025 Financial Results, Driven by Record Glaucoma Sales and Sustained Pipeline Progress Glaukos Corporation (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company focused on the development and commercialization of novel therapies for…
ICON Reports First Quarter 2025 Financial Results ICON plc (NASDAQ: ICLR), a leading global clinical research organization (CRO) driven by healthcare intelligence, today announced its financial results for the first quarter of 2025, which ended on March 31, 2025. CEO…